RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Posted: December 21, 2024 at 2:54 am

SYDNEY, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors.

Follow this link:
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Related Posts